Obesity Medicine 2024 - Tirzepatide Global Trials and Efficacy Insights (Live)
This session will inform HCPs on the tirzepatide molecule, the SURMOUNT global trial program for the treatment of obesity and overweight, and the safety and efficacy data disclosure for SURMOUNT-3 and SURMOUNT-4.
CME/CE Expiration Date: 5/26/24
*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.
Jamy Ard, MD
Deborah B. Horn, DO MPH MFOMA
Available Credit
- 1.00 AAPThis continuing medical education activity has been reviewed by the American Academy of Pediatrics and is acceptable for a maximum of 1.00 credits. These credits can be applied toward the AAP CME/CPD Award available to Fellows and Candidate Members of the American Academy of Pediatrics.
- 1.00 AMA PRA Category 1 Credit™The Obesity Medicine Association (OMA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Obesity Medicine Association designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the commensurate amount with the extent of their participation in the activity.